

INSULINA DEGLUDEC

Bibliografía

1. Tresiba. Ficha técnica. London (United Kingdom): European Medicines Agency (EMA); 2015. Disponible a: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002498/WC500138940.pdf
2. Committee for Medicinal Products for Human Use, 2012. Tresiba®. EMA/CHMP/557821/2012. London (United Kingdom): European Medicines Agency (EMA); 2012 [citado febrero 2016]. Disponible en: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/002498/WC500139010.pdf
3. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet* 2012;379(9825):1489-97.
4. Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. *Pediatric Diabetes*. 2015;16:164-176.
5. Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab* 2013;98(3):1154-62.
6. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet* 2012;379(9825):1498-507.
7. Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). *Diabetes Care* 2012;35(12):2464-71.
8. Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-Volume Insulin Degludec 200 units/mL Once Daily Improves Glycemic Control Similar to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. *Diabetes Care* 2013;36:2536-42.
9. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. *Diabetes Care* 2013;36(4):858-64.

10. Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. *Diabetes Obes Metab* 2013;15(9):826-32.
11. Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV et al. Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents. *Diabetes Obes Metab* 2013; 15: 760–766.
12. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. *Diabet Med* 2013; May 26. doi: 10.1111/dme.12243.
13. Jean-Marc Guettier, MDCM Clinical Perspective of Hypoglycemia Analyses and Results Endocrinologic and Metabolic Drugs Advisory Committee Meeting November 8, 2012 slide 24-25. Disponible en: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM330923.pdf>
14. FDA Briefing Document. NDA 203313 and NDA 203314. Insulin Degludec and Insulin Degludec/Aspart. Endocrinologic and Metabolic Drugs. Advisory Committee Meeting. November 8, 2012. Disponible en: <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm327015.pdf>.
15. Schimdt T. European Medicines Agency must take account of cardiovascular harm associated with degludec insulin. *BMJ* 2013;346:f3731.
16. Estrategia en Diabetes del Sistema Nacional de Salud. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2012 [citado febrero 2016]. Disponible en: http://www.aecosan.mssi.gob.es/AECOSAN/docs/documentos/nutricion/observatorio/estrategia_en_diabetes_del_sistema_nacional_de_salud_2012.pdf
17. Management of Diabetes: a national clinical guideline, 116. Scottish Intercollegiate Guidelines Network (SIGN); 2013 [citado febrero 2016]. Disponible en: <http://www.sign.ac.uk/pdf/sign116.pdf>.
18. Grupo de trabajo de la Guía de Práctica Clínica sobre Diabetes mellitus tipo 1. Guía de Práctica Clínica sobre Diabetes mellitus tipo 1. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad y Política Social. Agencia de Evaluación de Tecnologías Sanitarias del País Vasco-Osteba; 2012. Guías de Práctica Clínica en el SNS: OSTEBA n.º 2009/10.
19. Type 1 diabetes in adults: diagnosis and management. NICE guidelines NG17 . London (United Kingdom): National Institute for Health and Care Excellence (NICE); 2015 [citado febrero 2016]. Disponible en: <https://www.nice.org.uk/guidance/ng17>
20. Pautes per a l'harmonització del tractament farmacològic de la diabetis mellitus tipus 2. Barcelona: Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS). Departament de Salut. Generalitat de Catalunya; 2013 [citado mayo 2015]. Disponible a: http://catsalut.gencat.cat/web/.content/minisite/catsalut/proveidors_professionals/medicaments_farmacia/phf_apc/protocols/diabetis_mellitus_tipus2/pauta_diabetis_01.pdf
21. Type 2 diabetes in adults: management. NICE guidelines NG28 . London (United Kingdom): National Institute for Health and Care Excellence (NICE); 2015 [citado febrero 2016]. Disponible en: <http://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-adults-management-1837338615493>
22. Mata M., Cos FX, Morros R, Diego K, Barrot J, Berengué M, et al. Abordatge de la diabetis mellitus tipus 2 [en línia]. 2a ed. Barcelona: Institut Català de la Salut; 2013 (Guies de pràctica clínica i material docent, núm. 15). Disponible en: <http://www.gencat.cat/ics/professionals/guies/diabetis/diabetis.htm>